Testing preference elicitation methods in clinical case studies

Our researchers will test different methods for preference elicitation in clinical case studies. We will evaluate what patients think is relevant about their disease and its impact. We will look at which treatment options they prefer and their willingness to accept trade-offs between benefits and risks of their treatment. These methods will be evaluated at different decision points in the drug development process.

We are running clinical patient preference case studies in three disease areas, involving both  patient and clinical research partners in the PREFER project: lung cancer, rheumatoid arthritis and neuromuscular disorders. PhD students working in the project and partners from the pharmaceutical industry provide an additional eight more patient preference studies covering preferences for different kinds of treatment for haemophilia, rheumatoid arthritis, diabetes, multiple myeloma, chronic obstructive pulmonary disease, chronic pain and myocardial infarction. We are also using eye-tracking techniques to see how patients respond to a preference study using a methodology called discrete choice experiments (DCE).

Want to learn more? have a look at our case study catalogue. And if you want to know more about how we use different terms in PREFER, have a look at our glossary.

Find out about our studies! (Link removed)





  • Disclaimer: This website and its contents reflects the PREFER project's view and not the view of IMI, the European Union or EFPIA.


The Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115966. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).